Laura Lindley Tarter, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lupus Erythematosus, Systemic | 5 | 2024 | 2153 | 0.700 |
Why?
|
| Pre-Eclampsia | 1 | 2024 | 1261 | 0.450 |
Why?
|
| Premature Birth | 1 | 2024 | 1829 | 0.370 |
Why?
|
| Pregnancy Complications | 1 | 2024 | 2973 | 0.330 |
Why?
|
| Contraception | 2 | 2020 | 361 | 0.260 |
Why?
|
| Rheumatology | 3 | 2021 | 602 | 0.250 |
Why?
|
| Mitral Valve | 1 | 2013 | 1476 | 0.230 |
Why?
|
| Musculoskeletal Diseases | 2 | 2020 | 598 | 0.220 |
Why?
|
| Rheumatic Diseases | 2 | 2020 | 620 | 0.210 |
Why?
|
| Antibodies, Antinuclear | 1 | 2024 | 340 | 0.200 |
Why?
|
| Pericarditis | 1 | 2023 | 135 | 0.190 |
Why?
|
| Primary Ovarian Insufficiency | 1 | 2021 | 104 | 0.170 |
Why?
|
| Opportunistic Infections | 1 | 2021 | 377 | 0.150 |
Why?
|
| Hematologic Tests | 2 | 2020 | 239 | 0.140 |
Why?
|
| Breast Feeding | 1 | 2023 | 1363 | 0.120 |
Why?
|
| Infertility | 1 | 2021 | 656 | 0.110 |
Why?
|
| Arthralgia | 2 | 2020 | 456 | 0.110 |
Why?
|
| Takayasu Arteritis | 1 | 2014 | 103 | 0.100 |
Why?
|
| Pregnancy Outcome | 1 | 2024 | 2969 | 0.100 |
Why?
|
| Levamisole | 1 | 2011 | 36 | 0.100 |
Why?
|
| Endocardium | 1 | 2012 | 249 | 0.090 |
Why?
|
| Purpura | 1 | 2011 | 116 | 0.090 |
Why?
|
| Drug Contamination | 1 | 2011 | 151 | 0.090 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2014 | 575 | 0.080 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2011 | 282 | 0.080 |
Why?
|
| Ambulatory Care | 1 | 2021 | 2778 | 0.080 |
Why?
|
| Lupus Nephritis | 1 | 2013 | 320 | 0.080 |
Why?
|
| Cough | 1 | 2013 | 597 | 0.080 |
Why?
|
| Vaccination | 1 | 2021 | 3425 | 0.080 |
Why?
|
| Hydroxychloroquine | 1 | 2012 | 429 | 0.070 |
Why?
|
| Dyspnea | 2 | 2013 | 1352 | 0.070 |
Why?
|
| Antirheumatic Agents | 2 | 2020 | 1362 | 0.070 |
Why?
|
| Pregnancy | 3 | 2024 | 30253 | 0.070 |
Why?
|
| Cocaine | 1 | 2011 | 945 | 0.070 |
Why?
|
| Fever | 1 | 2013 | 1603 | 0.060 |
Why?
|
| Diagnosis, Differential | 3 | 2020 | 12969 | 0.060 |
Why?
|
| Infant, Newborn | 1 | 2024 | 26341 | 0.050 |
Why?
|
| Ultrasonography | 2 | 2014 | 5997 | 0.050 |
Why?
|
| Colchicine | 1 | 2023 | 255 | 0.050 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2012 | 2136 | 0.050 |
Why?
|
| Directly Observed Therapy | 1 | 2001 | 139 | 0.040 |
Why?
|
| Aspirin | 2 | 2023 | 3135 | 0.040 |
Why?
|
| Female | 9 | 2024 | 396159 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2012 | 5596 | 0.040 |
Why?
|
| Stroke | 1 | 2020 | 9750 | 0.040 |
Why?
|
| Skin | 1 | 2011 | 4479 | 0.040 |
Why?
|
| Kidney | 1 | 2013 | 7073 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2021 | 894 | 0.030 |
Why?
|
| Community Health Services | 1 | 2001 | 657 | 0.030 |
Why?
|
| Exanthema | 1 | 2020 | 501 | 0.030 |
Why?
|
| Humans | 11 | 2024 | 766011 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2020 | 1471 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2023 | 2269 | 0.030 |
Why?
|
| Fatigue | 1 | 2020 | 1551 | 0.030 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2001 | 1899 | 0.020 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2001 | 2204 | 0.020 |
Why?
|
| Young Adult | 2 | 2020 | 59870 | 0.020 |
Why?
|
| Recurrence | 1 | 2023 | 8505 | 0.020 |
Why?
|
| Consensus | 1 | 2021 | 3200 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2012 | 683 | 0.020 |
Why?
|
| Biopsy | 2 | 2012 | 6766 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 2020 | 1659 | 0.020 |
Why?
|
| Disease Management | 1 | 2020 | 2534 | 0.020 |
Why?
|
| Cocaine-Related Disorders | 1 | 2011 | 458 | 0.020 |
Why?
|
| Edema | 1 | 2012 | 761 | 0.020 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2020 | 2771 | 0.020 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2014 | 1430 | 0.020 |
Why?
|
| Necrosis | 1 | 2011 | 1613 | 0.020 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 3251 | 0.020 |
Why?
|
| Syndrome | 1 | 2011 | 3269 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 2012 | 4498 | 0.010 |
Why?
|
| Cardiomyopathies | 1 | 2012 | 2067 | 0.010 |
Why?
|
| Echocardiography | 1 | 2012 | 5042 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2020 | 36543 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2021 | 24299 | 0.010 |
Why?
|
| Haiti | 1 | 2001 | 553 | 0.010 |
Why?
|
| Public Health Practice | 1 | 2001 | 219 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2014 | 6545 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2023 | 65236 | 0.010 |
Why?
|
| Risk Factors | 1 | 2021 | 74870 | 0.010 |
Why?
|
| Brain | 1 | 2020 | 27177 | 0.010 |
Why?
|
| Drug Costs | 1 | 2001 | 1193 | 0.010 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2001 | 942 | 0.010 |
Why?
|
| Antitubercular Agents | 1 | 2001 | 1382 | 0.010 |
Why?
|
| United States | 1 | 2020 | 72914 | 0.010 |
Why?
|
| Poverty | 1 | 2001 | 2714 | 0.000 |
Why?
|
| Adult | 2 | 2014 | 223109 | 0.000 |
Why?
|
| Developing Countries | 1 | 2001 | 2912 | 0.000 |
Why?
|
| Middle Aged | 2 | 2012 | 223058 | 0.000 |
Why?
|
| Retrospective Studies | 1 | 2011 | 81522 | 0.000 |
Why?
|
| Male | 1 | 2020 | 363808 | 0.000 |
Why?
|